Mortality Rate and Associated Factors in Critically Ill Intubated Patients with Coronavirus Disease 2019 (COVID-19) at Pranangklao Hospital
DOI:
https://doi.org/10.14456/2022020105Keywords:
Anesthetics, Critical illnes, Coronavirus, COVID-19, Mortality rate, Intubation, SARS-CoV-2Abstract
Introduction: In the epidemic wave of the ongoing coronavirus disease 2019 (COVID-19) pandemic in April 2021. This study aimed to explore the 30-day mortality rate and its associated factors and anesthetic practice in critically ill COVID-19 patients who received intubation.
Methods: This retrospective cohort study was collected data from medical records in critically ill COVID-19 patients who received intubation and admitted to Pranangklao Hospital (PNKH) from April 1 to June 30, 2021.
Results: A total of 73 patients were admitted and intubated with the median age was 65 years (IQR = 18), 43 (58.9%) were male, 37 (50.7%) were body mass index (BMI) ≥ 30 kg/m2, and 60 (82.2%) had underlying diseases. The most common underlying diseases were hypertension (63.00%) and diabetes (47.90%). The 30-day mortality rate was 79.50%. Compared between the survivors (n = 15) and non-survivors (n = 58), the mortality significantly increased with age (P = .002), more underlying diseases (P = .007), having cough (RRadj 31.90, 95% CI = 1.67-610.65, P = .021), and more complications (RRadj 2.58, 95% CI = 1.02-6.51, P = .045). The anesthetics were used as follows: midazolam (80.95%), thiopental (40.48%), propofol (26.19%), and ketamine (23.81%). The muscle relaxants used in intubation included succinylcholine (90.48%) and rocuronium (9.52%).
Conclusions: Critically ill intubated COVID-19 patients showed a very high mortality rate that significantly increased with age, underlying diseases, and complications. Intubation treatment in vulnerable populations should be done cautiously to avoid adverse events.
Downloads

Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Asian Medical Journal and Alternative Medicine

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.